Literature DB >> 24451757

Considerations and controversies in the management of older patients with advanced cancer.

Supriya Gupta Mohile1, Heidi D Klepin1, Arati V Rao1.   

Abstract

The incidence of cancer increases with age. Oncologists need to be adept at assessing physiologic and functional capacity in older patients in order to provide safe and efficacious cancer treatment. Assessment of underlying health status is especially important for older patients with advanced cancer, for whom the benefits of treatment may be low and the toxicity of treatment high. The comprehensive geriatric assessment (CGA) is the criterion standard for evaluation of the older patient. The combined data from the CGA can be used to stratify patients into categories to better predict risk for chemotherapy toxicity as well as overall outcomes. The CGA can also be used to identify and follow-up on possible functional consequences from treatment. A variety of screening tools might be useful in the oncology practice setting to identify patients who may benefit from further testing and intervention. In this chapter, we discuss how the principles of geriatrics can help improve the clinical care of older adults with advanced cancer. Specifically, we discuss assessing tolerance for treatment, options for chemotherapy scheduling and dosing for older patients with advanced cancer, and management of under-recognized symptoms in older patients with cancer.

Entities:  

Year:  2012        PMID: 24451757     DOI: 10.14694/EdBook_AM.2012.32.168

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  3 in total

Review 1.  Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?

Authors:  Giuseppe Aprile; Caterina Fontanella; Eufemia Stefania Lutrino; Laura Ferrari; Mariaelena Casagrande; Giovanni Gerardo Cardellino; Gerardo Rosati; Gianpiero Fasola
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

2.  Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer.

Authors:  Sener Cihan; Hatice Odabas; Nuriye Yildirim Ozdemir; Dogan Yazilitas; Nalan Akgul Babacan
Journal:  World J Oncol       Date:  2015-02-14

3.  First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.

Authors:  Joshua E Allen; Roslyn N Crowder; Roslyn Crowder; Wafik S El-Deiry
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.